Abstract
Objective:
To examine associations of HLA class I and class II alleles with ankylosing spondylitis (AS) in three cohorts of patients of European, Asian and African ancestry.
Methods:
HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1 alleles were genotyped in 1948 unrelated white and 67 African-American AS patients from the Prospective Study of Outcomes in Ankylosing Spondylitis (PSOAS) cohort, the North American Spondylitis Consortium (NASC) and Australo-Anglo-American Spondyloarthritis Consortium (TASC), 990 white and 245 African American Controls and HLA-B alleles in 442 Han Chinese AS patients and 346 controls from Shanghai and Gansu, China. In addition to the case:control analyses, HLA-B*27 negative AS patients were analyzed separately, and logistic regression and “relative predispositional effects” (RPE) analyses were carried out to control for the major effect of HLA-B*27on disease susceptibility.
Results:
Although numerous associations were seen between HLA alleles and AS in whites, among HLA-B*27 negative AS patients, positive associations were seen with HLA-A*29, B*38, B*49, B*52, DRB1*11 and DPB1*03:01 and negative associations with HLA-B*07, -B*57, -DRB1*15:01, -DQB1*02:01 and -DQB1*06:02. Additional associations with HLA-B*14 and B*40 (B60) were observed via RPE analysis, which excludes the HLA-B*27 alleles. The increased frequency of HLA-B*40:01 and decreased frequency of HLA-B*07 was also seen in Han Chinese and African-Americans with AS. HLA-B*08 was decreased in whites with acute anterior uveitis.
Conclusions:
These data, analyzing the largest number of AS patients examined to date in three ethnic groups, confirm that other HLA class I and II alleles other than HLA-B*27 to be operative in AS predisposition.
Introduction
Studies of the contribution of MHC-encoded variants to the heritability of AS suggest that it is responsible for 20.44% of the genetic risk for the disease, with over 114 non-MHC variants identified to date contributing another 7.38% (1). Other MHC region genes have also been implicated in addition to HLA-B*27, including HLA-B*14 (2,3), HLA-B*60 (4-8), HLA-DRB1 (9-11), HLA-DPB1 (11,12), MICA (13,14), TNF-alpha1 (15), TAP1 (16) and LMP2 (11,17), although the level of association of these findings has not been definitive and with the exception of HLA-B*60 replication has not been universal.
HLA class I genes (HLA-A, -B and –C) and HLA class-II genes (HLA-DRA1, -DRB1, -DQA1, -DQB1, -DPA1, and -DPB1) encode cell-surface molecules that play an essential role in the immune defense against intracellular infections and in initiating an immune response to invading pathogens, respectively. Linkage disequilibrium (LD) with HLA-B*27 makes it difficult to resolve whether they play an independent role themselves, which would provide additional clues to AS pathogenesis, and potentially serve as biomarkers of diagnosis. Studies of direct HLA typing to date have been small and underpowered, providing inconsistent results.
Recently, we genotyped 7,264 MHC single-nucleotide polymorphisms (SNPs) in 9,069 AS cases and 13,578 population controls of European descent using the Illumina Immunochip microarray and controlling for the effects of HLA-B*27:02 and B*27:05, identified several other HLA-B allelic associations with AS, including significantly increased frequencies of HLA-B*13:02, B*40:01, B*40:02, B*47:01, B*51:01 and negative associations with HLA-B*07:02 and B*57:01, and association of HLA-A*02:01, HLA-DRB1*0:103 and HLA-DPB1 (18,19). In a Korean study, imputation was used to additionally show that HLA-C*15:02 is associated with AS susceptibility (19).
The purpose of this study was, in the largest reported series of patients to date for directly genotyped HLA alleles, to examine the relative contributions of HLA-class I and class II alleles, analyzing overall disease associations and conditioning on the presence of HLA-B*27 in three ethnic groups: 1948 whites of European ancestry, 442 Han Chinese, and 67 African Americans, the latter never having been examined for MHC associations (other than HLA-B*27 per se) previously.
Methods
Patient enrollment
White AS patients in this study came mostly from the Prospective Study of Outcomes in Ankylosing Spondylitis (PSOAS) cohort (20), a multi-ethnic study conducted at four U.S. academic institutions (The University of Texas Health-McGovern Medical School [UTH-H], Cedars-Sinai Medical Center, the University of California at San Francisco, and the National Institutes of Health Clinical Center) and from The North American Spondylitis Consortium (NASC) (n=408) (21). The black patients included 53 from the PSOAS study, seven from NASC, and seven other either from patients followed from the outpatient clinics at UTH or referred by Dr. Joel Taurog from the University of Texas Southwestern Medical School. All cases met modified New York criteria for AS (22). Controls were self-identified whites from the U.S. with no history of rheumatic disease obtained from unaffected nonconsanguinous spouses or household or friend controls the Scleroderma Family Registry and DNA repository (23) or the North American Spondylitis Consortium (21) (unrelated spouses or friends-75%) or from University of Texas-Houston Division Controls from Texas (25%). It should be noted that both the NASC and Scleroderma Family Registry controls and families came from all over the U.S., although were enriched from Texas and California (NASC) and from Texas, Maryland, Pennsylvania and Michigan (Scleroderma Family Registry) (23). Approximately one third of the US ASpatients were probands in the NASC study and 2/3 came from the PSOAS study (from which approximately half came from California, 30% from Texas, and 20% from the Mid-Atlantic region. All controls were screened by questionnaire for the presence of autoimmune disease or spondyloarthritis and were excluded if having such. For the HLA-B locus analyses, an additional 555 white British and Australian AS patients from the Australo-Anglo-American Spondylitis Consortium (TASC) were also analyzed. HLA-B locus typing from 442 Han Chinese AS patients and 346 unrelated Chinese controls were analyzed by the same statistical approaches. Though some of the HLA-typing was reported previously by us (24), additional statistical analyses were carried out for the present study on a significantly larger AS cohort heretofore unreported. The AS patients came from the clinics and hospitals in Shanghai and Jiangsu Province of China and the Chinese controls (who were free of any history of rheumatic disease) were obtained from a study project of Chinese population genetics at Fudan University in Shanghai. All subjects provided written informed consent. The study was approved by the Institutional Review Boards of all participating medical centers.
HLA Genotyping
Single Stranded Conformational Polymorphism (SSCP) typing, of HLA-A, -B and –C alleles, was performed using commercially available kits (Dynal, Inc.) on genomic DNA extracted from peripheral blood. HLA-DRB1, -DQA1, - DQB1 and -DPB1 typing was performed by standard oligotyping techniques with high resolution HLA-DRB1 typing further achieved by sequence analysis of PCR-amplified HLA-DRB1 exon 2, except for 18 of the African American AS patients, where the MHC class II alleles were determined by SSCP typing using commercially available kits (One Lambda, Inc). Genomic DNA from the Chinese AS patients and controls underwent the allele-specific polymerase chain reactions (PCR) using primers supplied in the SeCore kits, and then were followed by sequencing exon 2 and 3 of the HLA-B gene. The HLA SBT uTYPE 6.0 program (Life Technologies) was used in sequencing analysis and assigning HLA-B alleles.
The HLA-B genotyping in HLA-B*40 carriers was confirmed with sequence-based typing using SeCore Kits (Life Technologies, USA). The HLA SBT uTYPE 6.0 program (Life Technologies) was used in sequencing analysis.
Statistical Analysis
We constructed 2×2 tables and tested the proportion of alleles in cases vs. controls with adjusted chi square test using EPI-INFO (cdc.gov/epiinfo/index.html). Another method of “adjusting” for the effect of HLA-B*27 at the HLA-B locus is to mask the HLA-B*27 alleles and analyze the remaining alleles for association with phenotype by comparing their frequencies (relative predispositional effects analysis-RPE) (25, 26). Typically, RPEs are assessed by sequentially removing the alleles with the largest effect among those remaining (25). Such a procedure has no impact on loci other than HLA-B, as we are not removing individuals, but rather alleles. In addition to the univariable associations of each allele with AS, interaction effects between each allele and HLA-B*27 in relation to AS were examined using logistic regression models where the effects of each allele on AS were estimated for HLA-B*27 negative and positive patients separately. For the HLA-B analyses, this study has 94% power to detect an association with an additive odds ratio of 1.5 for an allele with minor allele frequency of 0.1 at nominal significance.
Results
The white patients in the PSOAS and NASC cohorts were strikingly similar in their clinical features, with psoriasis occurring in 10.4%, Crohn’s disease in 5.9%, ulcerative colitis in 3.5%, and reactive arthritis in 5.0%. Minor differences between the two cohorts included a slightly lower frequency of HLA-B*27 (85.4%) and uveitis (37%) in the PSOAS cohort compared to 98.5% and 44%, respectively, in the probands from the NASC cohort (the latter enriched for multicase families). The prevalence of HLA-B*27 and uveitis is higher in familial AS (27). Among the 61 blacks with AS studied who had clinical information available, uveitis occurred in 37.7%, psoriasis in 10.2%, and inflammatory bowel disease in 11.5%.
Examination of HLA-A, -B, and –C allele frequencies in all white AS patients and controls showed a number of highly significant associations at each locus (Table 1). HLA-B*27 occurred in 87.8% of the white AS patients compared to 7.6% of controls (p<1×10−9, odds ratio (OR)=87.7, 95% confidence interval (CI)=66.8 – 115.0), while HLA-B*27 homozygosity occurred in 3.5% of patients and 0.1% of controls (p<1×10−9, OR=35.9, 95% CI.=4.96 - 258.0) (data not shown-Table 1 shows allele frequencies). In addition to HLA-B*27, several other MHC class I alleles, including HLA-A*02, C*01, and C*02 were increased in frequency, whereas HLA-A*01, A*03, B*07, B*08, B*13, B*35, B*40, B*44, B*51, B*57, C*03, C*06 and C*07 were decreased in frequency (Table 1). Examination of HLA-DRB1 and -DQB1 allele frequencies in 790 patients and 704 controls demonstrated positive associations with HLA-DRB1*01:01, DRB1*01:03, and DRB1*04:04, as well as with DQB1*03:01 (in linkage disequilibrium (LD) with DRB1*01:03), DQB1*03:02 (in LD with DRB1*04:04) and DQB1*05:01 (in LD with DRB1*01:01). Examination of HLA-DPB1 alleles in 635 patients and 385 controls revealed an association with HLA-DPB1*03:01. HLA-DRB1*15:01 and DRB1*03:01 and their respective linked alleles DQB1*06:02 and DQB1*02:01 were deceased in frequency in the white AS patients.
Table 1.
Selected HLA Class I and II Associations with AS in Whites overall
| Allele | Cases freq.% | Control freq.% | # Cases | # Controls | Odds Ratio | P value |
|---|---|---|---|---|---|---|
| A*01 | 8.6 | 13.9 | 1326 | 1134 | 0.58 | 3.44 ×10−5 |
| A*02 | 35.1 | 27.9 | 1326 | 1134 | 1.40 | 1.56 ×10−4 |
| A*03 | 8.2 | 16.3 | 1326 | 1134 | 0.50 | <1 ×10−8 |
| B*07:00 | 5.9 | 15.0 | 3896 | 1980 | 0.36 | <1 ×10−8 |
| B*08:00 | 11.5 | 20.9 | 3896 | 1980 | 0.49 | <1 × 10 −8 |
| B*13:00 | 1.5 | 2.5 | 3896 | 1980 | 0.60 | 0.01 |
| B* 14:00 | 2.9 | 2.9 | 3896 | 1980 | 1.00 | 1.00 |
| B*15:00 | 3.3 | 7.1 | 3896 | 1980 | 0.45 | <1 × 10 −8 |
| B*27:00 | 46.1 | 3.8 | 3896 | 1980 | 21.4 | <1 × 10−8 |
| B*35:00 | 4.2 | 8.7 | 3896 | 1980 | 0.46 | <1 × 10−8 |
| B*38:00 | 1.3 | 1.5 | 3896 | 1980 | 0.91 | 0.78 |
| B*40 all | 5.4 | 7.6 | 3896 | 1980 | 0.69 | 0.001 |
| B*40:01 | 4.4 | 5.7 | 3896 | 1980 | 0.76 | 0.03 |
| B*40:02 | 0.7 | 1.2 | 3896 | 1980 | 0.59 | 0.09 |
| B*44:00 | 8.2 | 15.0 | 3896 | 1980 | 0.51 | <1 × 10−8 |
| B*51:00 | 2.7 | 3.8 | 3896 | 1980 | 0.70 | 0.03 |
| B*52:00 | 0.9 | 0.9 | 3896 | 1980 | 1.02 | 0.95 |
| B*57:00 | 1.3 | 3.7 | 3896 | 1980 | 0.34 | <1 × 10−8 |
| C*01:00 | 19.2 | 3.0 | 1302 | 1290 | 7.62 | <1 × 10−8 |
| C*06:00 | 4.5 | 9.8 | 1302 | 1290 | 0.43 | 2.1 ×10−7 |
| C*07:00 | 15.9 | 31.2 | 1302 | 1290 | 0.42 | <1 × 10−8 |
| DRB1*01:01 | 16.5 | 9.0 | 1580 | 1416 | 2.00 | <1 × 10−8 |
| DRB1*01:03 | 4.6 | 2.0 | 1580 | 1416 | 2.34 | 0.0001 |
| DRB1*03:01 | 6.0 | 12.0 | 1580 | 1416 | 0.46 | <1 × 10−8 |
| DRB1*04:04 | 6.5 | 2.5 | 1580 | 1416 | 2.72 | 3.0 ×10−7 |
| DRB1*15:01 | 8.7 | 14.7 | 1580 | 1416 | 0.56 | 4.8×10−7 |
| DQB1*02:01 | 6.3 | 12.7 | 1580 | 1416 | 0.46 | <1×10−9 |
| DQB1*03:01 | 26.4 | 19.2 | 1580 | 1416 | 1.29 | 0.006 |
| DQB1*03:02 | 14.3 | 9.2 | 1580 | 1416 | 1.65 | 2.0 × 10−5 |
| DQB1*05:01 | 19.9 | 12.6 | 1580 | 1416 | 1.71 | 1.2×10−7 |
| DQB1*06:02 | 9.2 | 15.1 | 1580 | 1416 | 0.57 | <1×10−9 |
| DPB1*02:01 | 12.8 | 10.3 | 1264 | 768 | 1.28 | 0.10 |
| DPB1*03:01 | 11.1 | 8.1 | 1264 | 768 | 1.42 | 0.03 |
| DPB1*04:01 | 42.5 | 44.3 | 1264 | 768 | 0.93 | 0.46 |
| DPB1*04:02 | 12.7 | 14.2 | 1264 | 768 | 0.88 | 0.38 |
Examining HLA-B*27-negative patients and controls, positive associations were seen with HLA-A*29, B*38, B*49 and B*52, as well as with HLA-DRB1*11 (Table 2). On the other hand, HLA-B*07, B*57, DRB1*15:01, DQB1*02:01 and DQB1*06:02 were significantly decreased in frequency. The association were seen with HLA-DPB1*03:01 in the overall group persisted in the HLA-B*27-negative white AS patients.
Table 2.
Associations in White HLA-B*27 Negative AS Patients
| Allele | Case freq.% | Control freq.% | No. case |
No. control |
Odds Ratio |
P value |
|---|---|---|---|---|---|---|
| A*01 | 14.5 | 14.2 | 110 | 1030 | 1.03 | 1.00 |
| A*02 | 24.5 | 27.7 | 110 | 1030 | 0.85 | 0.56 |
| A*03 | 10.0 | 16.6 | 110 | 1030 | 0.56 | 0.10 |
| A*11 | 7.3 | 3.5 | 110 | 1030 | 2.17 | 0.09 |
| A*24 | 12.7 | 8.8 | 110 | 1030 | 1.50 | 0.24 |
| A*29 | 9.1 | 3.5 | 110 | 1030 | 2.76 | 0.01 |
| B*07:00 | 10.2 | 15.4 | 472 | 1828 | 0.62 | 0.005 |
| B*08:00 | 9.3 | 21.9 | 472 | 1828 | 0.78 | 0.17 |
| B*13:00 | 2.5 | 2.7 | 472 | 1828 | 0.95 | 0.99 |
| B*14:00 | 4.4 | 3.1 | 472 | 1828 | 1.45 | 0.20 |
| B*38:00 | 3.2 | 2.8 | 472 | 1828 | 2.04 | 0.04 |
| B*40 all | 7.4 | 15.3 | 472 | 1828 | 0.90 | 0.70 |
| B*40:01 | 5.3 | 8.1 | 472 | 1828 | 0.87 | 0.60 |
| B*49:00 | 2.5 | 1.1 | 472 | 1828 | 2.36 | 0.03 |
| B*51:00 | 4.7 | 3.8 | 472 | 1828 | 1.23 | 0.49 |
| B*52:00 | 2.8 | 1.0 | 472 | 1828 | 2.85 | 0.006 |
| B*57:00 | 1.7 | 3.7 | 472 | 1828 | 0.45 | 0.04 |
| C*01:00 | 2.7 | 1.3 | 110 | 1146 | 2.11 | 0.43 |
| C*02:00 | 0.9 | 2.2 | 110 | 1146 | 0.41 | 0.59 |
| C*03:00 | 11.8 | 14.6 | 110 | 1146 | 0.79 | 0.52 |
| C*04:00 | 12.7 | 11.9 | 110 | 1146 | 1.08 | 0.91 |
| C*05:00 | 5.5 | 9.6 | 110 | 1146 | 0.54 | 0.21 |
| C*06:00 | 7.3 | 10.5 | 110 | 1146 | 0.67 | 0.37 |
| C*07:00 | 30.0 | 32.9 | 110 | 1146 | 0.87 | 0.61 |
| DRB1*01:01 | 4.7 | 7.9 | 148 | 948 | 0.58 | 0.24 |
| DRB1*01:03 | 1.4 | 1.8 | 148 | 948 | 0.75 | 0.97 |
| DRB1*03:01 | 6.8 | 12.2 | 148 | 948 | 0.52 | 0.07 |
| DRB1*04:04 | 4.7 | 2.3 | 148 | 948 | 2.09 | 0.16 |
| DRB1*11:00 | 17.6 | 9.6 | 148 | 948 | 2.01 | 0.005 |
| DRB1*15:01 | 6.1 | 14.8 | 148 | 948 | 0.37 | 0.006 |
| DQB1*02:01 | 6.8 | 12.7 | 148 | 948 | 0.50 | 0.05 |
| DQB1*03:01 | 26.4 | 19.2 | 148 | 948 | 1.51 | 0.06 |
| DQB1*03:02 | 8.8 | 8.5 | 148 | 948 | 1.59 | 1.00 |
| DQB1*05:01 | 10.2 | 11.4 | 148 | 948 | 0.74 | 0.40 |
| DQB1*06:02 | 6.8 | 15.1 | 148 | 948 | 0.41 | 0.009 |
| DPB1*01:01 | 2.9 | 4.9 | 102 | 678 | 0.59 | 0.54 |
| DPB1*02:01 | 12.8 | 10.3 | 102 | 678 | 1.47 | 0.25 |
| DPB1*03:01 | 11.1 | 8.1 | 102 | 678 | 1.42 | 0.03 |
| DPB1*04:01 | 42.5 | (44.3 | 102 | 678 | 0.93 | 0.46 |
| DPB1*04:02 | 12.7 | 14.1 | 102 | 678 | 0.88 | 0.38 |
Removing the effect of the presence of HLA-B*27 using RPE analysis, new associations emerged with HLA-B*14 and B*40:01 (Table 3) and the positive associations with HLA-B*38 and B*52 persisted, as did the negative associations with HLA-B*07 and B*57. Based on findings from HLA-B*27 stratified models for each allele, evidence for a significant interaction effect was observed for B*44 and B*49 (Table 3).
Table 3. HLA-B Allele Frequency Analysis in White AS Patients and Controls.
*The “-co” nomenclature for B*27 and B40 indicates the grouping of all such 4-digit alleles into 2-digit only.
| Univariable Model | Rel Predisp. Effects | Stratified Model | ||||||
|---|---|---|---|---|---|---|---|---|
| Allele | B*27(−) | B*27(+) | ||||||
| Odds Ratio |
P value | Odds Ratio | P value | Odds Ratio | P value | Odds Ratio |
P value | |
| *07:00 | 0.35 | <1×10−4 | 0.70 | 4×10−4 | 0.54 | <1×10−2 | n/a | n/a |
| *08:00 | 0.49 | <1×10−4 | 0.92 | 0.45 | 0.69 | 0.05 | n/a | n/a |
| *13:00 | 0.60 | 0.01 | 1.09 | 0.73 | 0.90 | 0.75 | n/a | n/a |
| *14:00 | 1.03 | 0.87 | 1.84 | 2×10−4 | 1.59 | 0.08 | n/a | n/a |
| *15:00 | 0.43 | <1×10−4 | 0.82 | 0.12 | 0.77 | 0.23 | 2.54 | 0.36 |
| *18:00 | 0.77 | 0.11 | 1.35 | 0.07 | 1.56 | 0.07 | n/a | n/a |
| 27all | 21.48 | 4×10−287 | n/a | n/a | n/a | n/a | n/a | n/a |
| *27:02 | 10.87 | 1×10−15 | n/a | n/a | n/a | n/a | n/a | n/a |
| *27:04 | 13.62 | 3×10−4 | n/a | n/a | n/a | n/a | n/a | n/a |
| *27:05 | 36.46 | 2×10−275 | n/a | n/a | n/a | n/a | n/a | n/a |
| *35:00 | 0.47 | <1×10−4 | 0.86 | 0.20 | 1.05 | 0.80 | 0.47 | 0.09 |
| *38:00 | 0.92 | 0.74 | 1.73 | 0.02 | 2.65 | <1×10−2 | 0.83 | 0.86 |
| *39:00 | 0.47 | <1×10−3 | 0.90 | 0.73 | 1.23 | 0.53 | 0.36 | 0.17 |
| 40all | 0.71 | 0.001 | 1.32 | 0.02 | 0.97 | 0.89 | 1.09 | 0.87 |
| *40:01 | 1.24 | 0.16 | 1.41 | 0.008 | 1.51 | 0.10 | 1.17 | 0.80 |
| *40:02 | 0.88 | 0.69 | 0.98 | 0.94 | 1.62 | 0.32 | n/a | n/a |
| *44:00§ | 0.50 | <1×10−4 | 1.03 | 0.92 | 1.04 | 0.82 | 0.34 | <1×10−2 |
| *49:00§ | 0.61 | 0.07 | 1.14 | 0.75 | 2.27 | 0.03 | 0.10 | <1×10−4 |
| *50:00 | 0.29 | <1×10−4 | 0.68 | 0.23 | 0.86 | 0.74 | n/a | n/a |
| *51:00 | 0.72 | 0.04 | 1.28 | 0.12 | 1.27 | 0.35 | 1.03 | 0.97 |
| *52:00 | 1.02 | 0.95 | 1.83 | 0.05 | 3.01 | <1×10−2 | n/a | n/a |
| *57:00 | 0.34 | <1×10−4 | 0.62 | 0.01 | 0.45 | 0.03 | 0.34 | 0.08 |
n/a: odds ratio is not estimable due to frequencies of zero in contingency tables of AS (case/control) and each allele (−/+).
significant interaction effect found with B*27 (−/+)
Amongst the Han Chinese AS patients, HLA-B*27 carriage was observed in 93.0% of the AS patients and 7.5% of the controls (p< × 10−9, OR=163) (data not shown). Ten (2.3%) of the 442 Chinese patients were homozygous for HLA-B*27 compared to none of the 346 controls (p=0.003). Looking at allele frequencies (Table 4), a higher odds ratio was observed for HLA-B*27:04 than HLA-B*27:05, and negative associations were observed for several other HLA-B alleles, including HLA-B*07, B*13, B*15, B*35, B*46 and B*51. A significant interaction effect between B*58 and HLA-B*27 in relation to AS was found (OR=1.24 among HLA-B*27 (−) patients; OR=0.32 among HLA-B*27 (+) patients). (Table 4).
Table 4.
HLA-B Allele Frequency Analysis in 442 Han Chinese AS Patients and 346 Controls
| Allele | AS Cases |
Cont rols |
Univariable Model | Rel Predisp. Effects |
Stratified Model | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| % | % | Odds Ratio |
P value | Odds Ratio |
P value | B*27(−) | B*27(+) | |||
| Odds Ratio | P value | Odds Ratio | P value | |||||||
| B*07:00 | 0.1 | 1.9 | 0.06 | 6.0×10−4 | 0.11 | 0.02 | 0.79 | 0.82 | n/a | n/a |
| B*08:00 | 0.2 | 0.7 | 0.31 | 0.16 | 0.57 | 0.78 | n/a | n/a | n/a | n/a |
| B*13:00 | 4.9 | 12.1 | 0.38 | <1×10−4 | 0.71 | 0.10 | 0.50 | 0.21 | 0.80 | 0.73 |
| B*14:00 | 0.2 | 0.1 | 2.35 | 0.46 | n/a | n/a | n/a | n/a | n/a | n/a |
| B*15:00 | 7.7 | 17.3 | 0.40 | <1×10−4 | 0.78 | 0.16 | 0.70 | 0.49 | 0.70 | 0.50 |
| B*18:00 | 0.2 | 0.1 | 1.57 | 0.71 | n/a | n/a | n/a | n/a | n/a | n/a |
| B*27all | 47.6 | 3.8 | 23.3 | <1×10−9 | n/a | n/a | n/a | n/a | n/a | n/a |
| B*27:04 | 34.8 | 2.3 | 22.6 | <1×10−9 | n/a | n/a | n/a | n/a | n/a | n/a |
| B*27:05 | 10.9 | 1.3 | 9.24 | <1×10−9 | n/a | n/a | n/a | n/a | n/a | n/a |
| B*27:15 | 1.4 | 0 | n/a | 0.04 | n/a | n/a | n/a | n/a | n/a | n/a |
| B*35:00 | 1.8 | 4.5 | 0.32 | <1×10−3 | 0.86 | 0.20 | 0.26 | 0.20 | n/a | n/a |
| B*38:00 | 1.6 | 2.9 | 0.53 | 0.08 | 1.0 | 1.0 | 1.23 | 0.79 | 0.23 | 0.03 |
| B*39:00 | 1.8 | 1.6 | 1.26 | 0.57 | 2.13 | 0.08 | 5.12 | 0.01 | 0.75 | 0.79 |
| B*40all | 10.5 | 12.9 | 0.86 | 0.38 | 1.63 | 0.003 | 1.90 | 0.10 | 6.04 | 0.08 |
| B*40:01 | 6.5 | 8.9 | 0.84 | 0.4 | 1.41 | 0.008 | 2.21 | 0.06 | 3.23 | 0.26 |
| B*40:02 | 1.5 | 2.5 | 0.67 | 0.3 | 0.98 | 0.94 | 1.40 | 0.66 | n/a | n/a |
| B*44:00 | 1.2 | 2.3 | 0.61 | 0.22 | 1.00 | 1.00 | 2.53 | 0.17 | 0.50 | 0.52 |
| B*46:00 | 4.5 | 9.8 | 0.44 | <1×10−3 | 0.83 | 0.44 | 0.45 | 0.20 | 1.19 | 0.82 |
| B*50:00 | 0.3 | 0 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| B*51:00 | 4.4 | 8.8 | 0.47 | <1×10−3 | 0.91 | 0.75 | 0.89 | 0.81 | 2.18 | 0.45 |
| B*52:00 | 1.7 | 2.8 | 0.61 | 0.15 | 1.14 | 0.84 | 1.09 | 0.91 | n/a | n/a |
| B*57:00 | 0.6 | 0.6 | 0.98 | 0.97 | 1.81 | 0.58 | 2.64 | 0.39 | n/a | n/a |
| B*58:00§ | 3.9 | 7.2 | 0.52 | 0.01 | 1.0 | 0.98 | 1.24 | 0.68 | 0.32 | 0.03 |
n/a: odds ratio is not estimable due to frequencies of zero in contingency tables of AS (case/control) and each allele (−/+).
significant interaction effect found with B*27 (−/+)
Among black subjects, HLA-B*27 occurred in 40 of 67 AS patients (59.7%) compared to 5 of 245 controls (2.0%) (p< × 10−9, OR=71.1) (Table 5). HLA-B*40:01 occurred in 4 of the 67 AS patients compared to 2 of 245 controls (p=0.03, OR=7.7)(Fisher’s exact). HLA-B*35 and B*42 were decreased in frequency. HLA-B*07 was also decreased in frequency, as seen in whites and Han Chinese, though the results were not significant (p=0.15) unless one applies a one tailed p value by Fisher’s exact testing (p=0.048, OR=0.46). Weak associations encountered with HLA-DRB1*08 and DQB1*03:01. The frequencies of IBD, psoriasis and reactive arthritis were too low for meaningful statistical analyses.
Table 5.
Selected HLA Allele Frequencies in African American AS patients and Controls*
| Allele | AS Patients (%) |
2×N++ | Controls (%) | 2×N | Odds Ratio |
P value** |
|---|---|---|---|---|---|---|
| B*07:00 | 3.7 | 134 | 7.8 | 490 | 0.46 | 0.15 |
| B*08:00 | 2.2 | 134 | 6.1 | 490 | 0.35 | 0.12 |
| B*14:00 | 1.5 | 134 | 2.9 | 490 | 0.52 | 0.56 |
| B*15:00 | 10.5 | 134 | 11.0 | 490 | 0.94 | 0.97 |
| B*27:00 | 29.9 | 134 | 1.0 | 490 | 41.3 | <1 × 10−8 |
| B*35:00 | 2.2 | 134 | 8.6 | 490 | 0.24 | 0.02 |
| B*40:00 | 3.0 | 134 | 1.4 | 490 | 2.12 | 0.40 |
| B*40:01 | 3.0 | 134 | 0.4 | 490 | 7.51 | 0.03 |
| B*42:00 | 3.7 | 134 | 10.3 | 490 | 0.34 | 0.03 |
| B*44:00 | 3.0 | 134 | 6.9 | 490 | 0.41 | 0.14 |
| B*51:00 | 0.8 | 134 | 3.5 | 490 | 0.21 | 0.17 |
| B*57:00 | 3.0 | 134 | 4.9 | 490 | 0.60 | 0.48 |
| B*58:00 | 4.5 | 134 | 7.8 | 490 | 0.56 | 0.26 |
| DRB1*01:01 | 7.7 | 130 | 4.6 | 482 | 1.74 | 0.23 |
| DRBl*15:01/03 | 13.1 | 130 | 11.6 | 482 | 1.14 | 0.76 |
| DRB1*03:01 | 3.1 | 130 | 6.2 | 482 | 0.48 | 0.24 |
| DRB1*03:02 | 2.3 | 130 | 6.2 | 482 | 0.36 | 0.13 |
| DRB1*04 | 10.0 | 130 | 6.0 | 482 | 1.74 | 0.16 |
| DRB1*07:00 | 3.9 | 130 | 7.3 | 482 | 0.51 | 0.23 |
| DRB1*08:00 | 10.0 | 130 | 5.0 | 482 | 2.12 | 0.05 |
| DRB1*11 | 12.3 | 130 | 12.0 | 482 | 1.02 | 1.00 |
| DRB1*13 | 21.5 | 130 | 19.1 | 482 | 1.16 | 0.61 |
| DQB1*02:01 | 3.1 | 130 | 6.6) | 482 | 0.45 | 0.19 |
| DQB1*03:01 | 27.7 | 130 | 19.5 | 482 | 1.58 | 0.05 |
| DQB1*03:02 | 7.7 | 130 | 4.8 | 482 | 1.66 | 0.28 |
| DQB1*04:02 | 4.6 | 130 | 7.9 | 482 | 0.56 | 0.28 |
| DQB1*05:01 | 17.7 | 130 | 11.6 | 482 | 1.64 | 0.09 |
| DQB1*06:02 | 16.9 | 130 | 13.9 | 482 | 1.26 | 0.47 |
| DPB1*01:01 | 16.2 | 130 | 26.5 | 132 | 0.53 | 0.06 |
| DPB1*02:01 | 15.4 | 130 | 12.1 | 132 | 1.32 | 0.56 |
| DPB1*03:01 | 9.2 | 130 | 7.6 | 132 | 1.24 | 0.80 |
| DPB1*04:01 | 14.6 | 130 | 9.1 | 132 | 1.71 | 0.23 |
| DPB1*04:02 | 7.7 | 130 | 8.3 | 132 | 0.92 | 1.00 |
| DPB1*13:01 | 6.9 | 130 | 3.0 | 132 | 2.42 | 0.23 |
| DPB1*17:01 | 6.9 | 130 | 11.2 | 132 | 0.59 | 0.32 |
Unless stated, the p-values shown were multiplied by the number of alleles examined at each locus. Alleles with frequencies of <5% were not examined unless potential biologic relevance was perceived.
After removing the effect of B*27, HLA-B*40:01 occurred in 4 of 94 genotypes in patients compared to 7 of 450 genotypes in controls, p=0.157, OR=3.03
These represent uncorrected p-values. These were no longer significant after applying Bonferroni’s correction
Two patients previously typed for HLA-B did not have DNA available for MHC class II typing
AAU occurred in 380 of 1389 with clinical data available (27.4%)(Table 6). HLA-B*27 occurred in 92.9% compared to 85.0% of those without AAU (p=1.4 × 10−4, OR=2.3). Neither of the two most common HLA-B*27 subtypes seen in whites (B*27:02 and B*27:05) were selectively associated with AAU, independent of their association with AS. Among blacks with AAU, 78.3% were HLA-B*27 positive compared to 42.1% without AAU (p=0.013, OR=4.95). The frequencies of IBD, psoriasis and reactive arthritis were too low for meaningful statistical analyses.
Table 6.
HLA-Class I and II Associations with AS in Uveitis in Whites AS Cases
| Allele | AS with Uveitis % |
AS w/o Uveitis % |
No. AS w AAU | No. AS w/o AAU |
Odds Ratio | P value |
|---|---|---|---|---|---|---|
| A*01 | 5.7 | 9.6 | 334 | 984 | 0.57 | 0.04 |
| A*02 | 34.4 | 35.5 | 334 | 984 | 0.96 | 0.78 |
| A*03 | 10.0 | 11.3 | 334 | 984 | 0.86 | 0.54 |
| B*07:00 | 5.5 | 5.5 | 760 | 2018 | 1.01 | 1.00 |
| B*08:00 | 5.8 | 12.0 | 760 | 2018 | 0.43 | 5.1×10−4 |
| B*13:00 | 1.8 | 1.3 | 760 | 2018 | 1.44 | 0.36 |
| B*14:00 | 2.4 | 3.5 | 760 | 2018 | 0.68 | 0.18 |
| B*27 all | 48.6 | 44.9 | 760 | 2018 | 1.16 | 0.08 |
| B*27:02 | 4.6 | 3.6 | 760 | 2018 | 1.29 | 0.28 |
| B*27:05 | 42.8 | 39.6 | 760 | 2018 | 1.14 | 0.15 |
| B*35:00 | 4.9 | 4.5 | 760 | 2018 | 1.10 | 0.72 |
| B*38:00 | 1.3 | 1.9 | 760 | 2018 | 0.68 | 0.35 |
| B*40 all | 5.8 | 5.2 | 760 | 2018 | 1.12 | 0.61 |
| B*40:01 | 4.3 | 4.3 | 760 | 2018 | 1.01 | 1.00 |
| B*40:02 | 1.1 | 0.5 | 760 | 2018 | 2.03 | 0.20 |
| B*44:00 | 6.7 | 7.6 | 760 | 2018 | 0.83 | 0.31 |
| B*51:00 | 2.6 | 1.1 | 760 | 2018 | 1.12 | 0.61 |
| B*57:00 | 1.1 | 1.4 | 760 | 2018 | 0.76 | 0.61 |
| C*01:00 | 19.4 | 18.9 | 324 | 972 | 1.03 | 0.90 |
| C*02:00 | 27.2 | 24.3 | 324 | 972 | 1.62 | 0.33 |
| C*06:00 | 5.3 | 4.2 | 324 | 972 | 1.26 | 0.50 |
| C*07:00 | 14.5 | 16.5 | 324 | 972 | 0.86 | 0.46 |
| DRB1*01:01 | 17.2 | 16.1 | 430 | 1150 | 1.08 | 0.64 |
| DRB1*01:03 | 4.2 | 4.5 | 430 | 1150 | 0.92 | 0.87 |
| DRB1*03:01 | 4.9 | 6.4 | 430 | 1150 | 0.76 | 0.30 |
| DRB1*04:04 | 13.1 | 12.0 | 430 | 1150 | 1.10 | 0.77 |
| DRB1*08:01 | 12.3 | 5.9 | 430 | 1150 | 1.64 | 0.12 |
| DRB1*15:01 | 10.9 | 7.7 | 430 | 1150 | 1.48 | 0.05 |
| DQB1*02:01 | 4.9 | 6.9 | 430 | 1150 | 0.70 | 0.19 |
| DQB1*03:02 | 15.1 | 13.8 | 430 | 1150 | 1.11 | 0.57 |
| DQB1*05:01 | 19.8 | 19.7 | 430 | 1150 | 1.01 | 1.00 |
| DQB1*06:02 | 10.9 | 8.4 | 430 | 1150 | 1.35 | 0.14 |
| DPB1*01:01 | 2.8 | 3.3 | 322 | 940 | 0.84 | 0.79 |
| DPB1*02:01 | 12.4 | 13.0 | 322 | 940 | 0.95 | 0.87 |
| DPB1*03:01 | 11.5 | 11.0 | 322 | 940 | 1.06 | 0.87 |
| DPB1*04:01 | 41.3 | 43.2 | 322 | 940 | 0.93 | 0.60 |
| DPB1*04:02 | 12.4 | 12.9 | 322 | 940 | 0.96 | 0.91 |
Discussion
HLA-B*27 is the major genetic association with AS in all major ethnic groups. Association of other MHC Class I and II loci with either AS specifically (3-8, 10-12) or spondyloarthritis in general (2,9) have been suggested, but have been confounded due to LD between HLA-B and the MHC class II loci. In this study, by conducting stratified analyses of HLA-B*27, we have shown associations with other MHC alleles that cannot be attributed to LD with HLA-B*27 in a moderately large number of AS patients from three ethnic groups. This study also analyzes these alleles in the largest collection of HLA-B*27 negative AS patients reported to date. We confirm by direct HLA typing some of the associations we previously reported by imputation (19).
HLA-B60 is a serologically defined specificity that correlates at the DNA level with HLA-B*40:01 (23). We were able to confirm the association with HLA-B*40:01 with AS in three ethnic groups. In this study, the largest to date employing direct HLA-typing, we were able to confirm the positive association with HLA-B60 (B*40), especially B*40:01, seen in other studies of whites by direct typing (4-7) and by imputed alleles (19) and of Taiwanese Chinese (8). We were also able to confirm the negative association with HLA-B*07 and B*57that we reported previously in whites by imputation (19) and in the case of B*07 in Han Chinese by DNA sequencing (24). The association seen with HLA-B*14, albeit only by RPE analysis, is compatible with what has been observed in French SpA families (2) as well as in African blacks (3). The association with HLA-B*38 seen most strikingly in HLA-B*27 negative patients is interesting, given its known association with psoriatic arthritis (29), although this was not seen in the Chinese cohort, where a weak association was described with HLA-B*39 (HLA-B*38 and B*39 being “splits” of the parent specificity HLA-B*16 (http://hla.alleles.org/antigens/broads_splits.html).
We observed an association with HLA-A*02 in the overall cohort that was not seen in the smaller HLA-B*27 negative cohort. This is compatible with the independent association with HLA-A*02:01 that we observed in a much larger patient cohort by imputation (18), although in the current study we were not able to resolve the association to the 4 digit level. Associations with HLA-DRB1*01 and HLA-DRB1*04:04 seen here have previously been described in UK AS patients and from French spondyloarthritis families (2,10), although the lack of confirmation in HLA-B*27 negatives does not allow us to rule out that this may reflect LD with HLA-B*27. Similarly, the association with HLA-DRB1*01:03 that we observed by imputation (19) was again seen here, but was not seen in the HLA-B*27 negatives. HLA-DRB1*01:03 is also strongly associated with inflammatory bowel disease, (30) in particular where associated with peripheral spondyloarthritis (31). On the other hand, the decreased frequency of HLA-DRB1*15:01 and its linked allele DQB1*06:02 overall and in the HLA-B*27 negatives confirms what we have observed by imputation analysis in a larger cohort (19), now seen by direct HLA typing. An increased frequency of HLA-B*14 has been observed in French SpA families (2) and in African AS patients (3) in other studies.
We were not able to confirm all the associations by direct HLA typing we previously described by imputation (19).In some cases, even with the rather large number of patients studied (1948 whites), given the low odds ratios (<1.5) there may have not have been adequate power. Alternatively, although the patients and controls were from all over the U.S., ancestry informative markers were not examined in the controls and we cannot rule out potential stratification issues. We previously described an association with HLA-B*51 by imputation, seen only in a conditional regression analysis, which we could not confirm here, even by RPE analysis. However, we did find an association with HLA-B*52 in whites, both in the HLA-B*27 negatives and in the overall cohort. HLA-B*51 and B*52 are well-recognized “splits” of the parent specificity HLA-B5 (http://hla.alleles.org/antigens/broads_splits.html), and, although HLA-B*51 was decreased overall, it was increased in frequency in the HLA-B*27 negatives and by RPE analysis, albeit not significantly. HLA-B*51 was significantly reduced in the Chinese cohort overall, but having controlled for the presence of HLA-B*27 by RPE, no association was observed. We were unable to establish an independent association with HLA-B*13, an allele long associated with psoriasis, described previously by imputation in whites (19). However, as with HLA-B*51, HLA-B*13 was reduced in the overall Han Chinese dataset, but having controlled for HLA-B*27 no association was observed. HLA-B*47, observed by imputation as AS-associated (19), only occurred in five AS patients, and hence was too uncommon to establish as an AS association (data not shown).
The association of HLA-DPB1*03:01 with AS seen in whites, further extends what was demonstrated previously in smaller cohorts (11,12). This is compatible with the association of SNPs around the HLA-DPB1 locus recently established by imputation (19). We did not examine HLA-DPA1 alleles, and so could not confirm the associations with HLA-DPA1*01:02 and DPA1*01:03 reported by Díaz-Peña et al (12). However, we did not observe any association with HLA-DPB1*13:01 that was seen in their cohort..
We could not confirm some other associations described in smaller AS or SpA cohorts elsewhere (32-34) perhaps due to clinical heterogeneity. One small recent study of HLA-A, -B, -C and DRB1 alleles in 75 Moroccan AS patients reported an allele frequency of HLA-B*27 of 32%, with associations also seen with B*57, C*02 and DRB1*15 and negative associations with HLA-B*35 and B*49 (32). The reasons for the discrepancies of these data and ours are hard to interpret given the small size of the cohort, which precluded examination of HLA-B*27 negatives. Another recent study of 189 Colombian patients with SpA (including 87 with AS, but also reactive arthritis and undifferentiated SpA) found associations with HLA-B*15 as well as with HLA-DRB1*01 and HLA-DRB1*04, as well as with HLA-B*27, which occurred at an allele frequency of 26.2% (33). Again, the small size of the cohort of AS patients did not allow examination of HLA-B*27 negatives.
The size of the black AS cohort was small (n=67 patients), which would have restricted the statistical power of our observations. Nevertheless, we were able to confirm the positive association with HLA-B*40:01 and the negative association with B*07, for the first time in this ethnic group. The finding of HLA-B*27 in 60% of the black AS patients is compatible with what was reported by Khan et al. in a smaller cohort several years ago (35).
We were able to confirm the association with HLA-DRB1*01:03 as observed by Cortes et al by imputation (19), although not an association of HLA-DRB1*08 with either AS or the uveitis phenotype, as has been reported elsewhere (10, 11), in fact HLA-DRB1*08 was actually decreased in those with AAU. We did observe a significant association with the presence of HLA-B*27 and the occurrence of AAU in our patients, as also seen by imputation (34) but not the higher frequency of HLA-B*27 homozygosity seen there. Otherwise the most robust association, albeit negative, was the decreased frequency of HLA-B*08 in those with AAU, which contrasts what was observed by imputation, where an increased frequency of a single nucleotide polymorphism (SNP) associated with HLA-B*08, namely rs115937001, was observed (36). The reasons for this was unclear, as the odds ratio of 1.8 in that larger group of 1,711 patients with uveitis would suggest that there should have been sufficient power in this cohort of 380 patients with AAU to confirm this.
Thus, in the largest study of direct HLA typing of AS patients and controls from three ethnic groups (and the only one examining African-American blacks other than HLA-B*27), these data show that the impact of the MHC on AS susceptibility extends beyond HLA-B*27. Many (though not all) of the observations made in a prior larger study of imputed HLA alleles (19) are seen here. That positive and negative associations of certain of these alleles cross ethnic boundaries suggests an independent role of both MHC class I and II alleles in influencing susceptibility to AS and subsets thereof.
What is already known about this subject?
Although the association of HLA-B27 with ankylosing spondylitis (AS) is well established, as is the association with B60 (B*40), those of other HLA alleles that have been reported in smaller studies have been inconsistent or unconfirmed.
The role of HLA alleles other than HLA-B27 have not been studied in African Americans
In a large recent study imputing HLA alleles in whites from our group, a number of new HLA associations have been reported.
What does this study add?
In this study, the largest to date in whites and Asians and the first to date in African Americans (other than HLA-B27) to employ direct HLA typing, a number of the HLA-associations we described by imputing HLA alleles in whites are confirmed not only in whites but also in Chinese and African American AS patients. A number of other HLA association not seen in the imputation analysis, including some seen in previous small studies, especially in the largest cohort of HLA-B27 negative AS patients reported to date, are seen with other HLA-B, DRB1, DQB1 and DPB1 alleles, some reported in earlier smaller studies and other novel associations (though the latter because of possible power or stratification issues will need confirmation). This study shows a role for not only HLA-class I alleles other that HLA-B27 but also class II HLA genes in predisposition to AS and subsets thereof, independent of linkage with HLA-B27.
How might this impact on clinical practice?
This study gives the clinician not only a better understanding of the relative inputs of HLA alleles other than HLA-B27 in predisposition to AS, but also better informs how to interpret HLA-B27 typing results in blacks.
Acknowledgements:
These data previously presented at the American College of Rheumatology meeting in 2014.and published as a conference abstract
Funding info:
This study was supported by the National Institutes of Health-National Institute of Allergy and Infectious Diseases (NIH-NIAIS) grant UO1 AI09090 (Drs. Zhou, Reveille), National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIH-NIAMS) grants R01 AR-46208 and 2P01AR052915-06A1 (Dr. Reveille), and by University Clinical Research Grants M01-RR-02558 (The University of Texas Health Science Center at Houston), and M01-RR-000425 (Cedars-Sinai Medical Center) and by a grant from the Spondylitis Association of America. Matthew A. Brown was funded by a National Health and Medical Research Council (Australia) Senior Principal Research Fellowship. Lianne Gensler is supported by the Rosalind Engelman research center at the University of California, San Francisco. Michael Ward is funded by the Intramural Research Program, NIAMS/NIH.
Footnotes
Competing interests:
None
Ethical approval information: The Internal Review Boards at The University of Texas-Health McGovern Medical School, The University of California-San Francisco, Cedars-Sinai Medical Center, The NIH-NIAMS Clinical Center, The Princess Alexandra Hospital (Brisbane), and Fudan University reviewed and approved this study
Data sharing statement:
We would be happy to share the data published in this manuscript. There are no unpublished data referable to the work included here.
References
- 1.Ellinghaus D, Jostins L, Spain SL, Cortes A, Bethune J, Han B, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet. 2016. May;48(5):510–8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Breban M Genetic studies of spondylarthropathies. French Spondylarthropathy Genetic Study Group.Ann Med Interne (Paris) 1998. April;149(3):142–4. [PubMed] [Google Scholar]
- 3.López-Larrea C, Mijiyawa M, González S, Fernández-Morera JL, Blanco-Gelaz MA, Martínez-Borra J, López-Vázquez A. Association of ankylosing spondylitis with HLA-B*1403 in a West African population. Arthritis Rheum 2002. November;46 (11):2968–71 [DOI] [PubMed] [Google Scholar]
- 4.Robinson WP, van der Linden SM, Khan MA, Rentsch HU, Cats A, Russell A, Thomson G. HLA-Bw60 increases susceptibility to ankylosing spondylitis in HLA-B*27+ patients. Arthritis Rheum 1989. September; 32(9): 1135–41 [DOI] [PubMed] [Google Scholar]
- 5.Brown MA, Pile KD, Kennedy LG, Calin A, Darke C, Bell J, et al. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis 1996. April;55(4): 268–270 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.van Gaalen FA, Verduijn W, Roelen DL, Böhringer S, Huizinga TW, van der Heijde DM, Toes RE. Epistasis between two HLA antigens defines a subset of individuals at a very high risk for ankylosing spondylitis. Ann Rheum Dis 2013. June;72(6):974–8. [DOI] [PubMed] [Google Scholar]
- 7.Díaz-Peña R, Vidal-Castiñeira JR, López-Vázquez A, López-Larrea C. HLA-B*40:01 Is Associated with Ankylosing Spondylitis in HLA-B*27-positive Populations. J Rheumatol. 2016. June;43(6):1255–6. [DOI] [PubMed] [Google Scholar]
- 8.Wei JC, Sung-Ching HW, Hsu YW, Wen YF, Wang WC, Wong RH, et al. Interaction between HLA-B60 and HLA-B*27 as a Better Predictor of Ankylosing Spondylitis in a Taiwanese Population. PLoS One. 2015. October 15;10(10):e0137189. doi: 10.1371/journal.pone.0137189.eCollection 2015 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Said-Nahal R, Miceli-Richard C, Gautreau C, Tamouza R, Borot N, Porcher R,et al. The role of HLA genes in familial spondyloarthropathy: a comprehensive study of 70 multiplex families Ann Rheum Dis 2002. March ;61(3):201–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Brown MA, Kennedy LG, Darke C, Gibson K, Pile KD, Shatford JL, Taylor A, Calin A, Wordsworth BP. The effect of HLA-DR genes on susceptibility to and severity of ankylosing spondylitis. Arthritis Rheum. 1998. March;41(3):460–5 [DOI] [PubMed] [Google Scholar]
- 11.Ploski R, Flato B, Vinje O, Maksymowych W, Førre O, Thorsby E. Association to HLA-DRB1*08, HLA-DPB1*0301 and homozygosity for an HLA-linked proteasome gene in juvenile ankylosing spondylitis. Human Immunology 1995. October; 44 (2), 88–96. [DOI] [PubMed] [Google Scholar]
- 12.Díaz-Peña R, Aransay AM, Bruges-Armas J, Lñpez-Vázquez A, Rodríguez-Ezpeleta N, Mendibil I, et al. Fine mapping of a major histocompatibility complex in ankylosing spondylitis: association of the HLA-DPA1 and HLA-DPB1 regions. Arthritis Rheum 2011. November;63 (11):3305–12. [DOI] [PubMed] [Google Scholar]
- 13.Ricci-Vitiani L, Vacca A, Potolicchio I, Scarpa R, Bitti P, Sebastiani G, et al. MICA gene triplet repeat polymorphism in patients with HLA-B*27 positive and negative ankylosing spondylitis from Sardinia. J Rheumatol 2000. September;27 (9):2193–7 [PubMed] [Google Scholar]
- 14.Zhou X, Wang J, Zou H, Ward MM, Weisman MH, Espitia MGG, et al. MICA, a gene contributing strong susceptibility to ankylosing spondylitis.Ann Rheum Dis 2014. August;73(8):1552–7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Hohler T, Schaper T, Schneider PM, Meyer zum Büschenfelde KH Märker-Hermann E. Association of different tumor necrosis factor alpha promoter allele frequencies with ankylosing spondylitis in HLA-B*27 positive individuals. Arthritis Rheum 1998; August; 41(8):1489–92. [DOI] [PubMed] [Google Scholar]
- 16.Fraile A, Collado MD, Mataran L, Martin J, Nieto A. TAP1 and TAP2 polymorphism in Spanish patients with ankylosing spondylitis. Exp Clin Immunogenet 2000; 17(4):199–204 [DOI] [PubMed] [Google Scholar]
- 17.Maksymowych WP, Wessler A, Schmitt-Egenolf M, Suarez-Almazor M, Ritzel G, Von Borstel RC, et al. Polymorphism in an HLA linked proteasome gene influences phenotypic expression of disease in HLA-B*27 positive individuals. J Rheumatol 1994. April; 21(4): 665–9 [PubMed] [Google Scholar]
- 18.Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T, Leo P, et al. Multiple novel loci harbouring common and rare variants implicated in ankylosing spondylitis. Nature Genetics 2013. July; 45(7):730–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Cortes A, Pulit SL, Leo PJ, Pointon JJ, Robinson PC, Weisman MH, et al. Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. Nat Commun 2015. May 21;6:7146. doi: 10.1038/ncomms8146. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Ward MM, Weisman MH, Davis JC, Reveille JD. Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum 2005. October 15; 53(5): 710–717. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Zhang G, Luo J, Bruckel J, Weisman MA, Schumacher HR, Khan MA, et al. Genetic studies in familial ankylosing spondylitis susceptibility. Arthritis Rheum. 2004. July; 50(7): 2246–54 [DOI] [PubMed] [Google Scholar]
- 22.van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984. April; 27(4):361–8 [DOI] [PubMed] [Google Scholar]
- 23.Assassi S, Arnett FC, Reveille JD, Gourh P, Mayes MD. Clinical, immunologic, and genetic features of familial systemic sclerosis. Arthritis Rheum. 2007. June;56(6):2031–7. [DOI] [PubMed] [Google Scholar]
- 24.Lin Y, Wang J, Guo X, Espitia MG, Chen E, Assassi S, et al. Profiling of HLA-B Alleles for Association Studies with Ankylosing Spondylitis in the Chinese Population. Open Rheumatol J. 2013. August 19; 7:51–4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Payami H, Joe S, Farid NR, Stenszky V, Chan SH, Yeo PP, et al. Relative predispositional effects (RPEs) of marker alleles with disease: HLA-DR alleles and Graves disease. Am J Hum Genet. 1989. October;45(4):541–6. [PMC free article] [PubMed] [Google Scholar]
- 26.Mu H, King MC, Criswell LA. Relative predispositional effects and mode of inheritance of HLA-DRB1 alleles among community-based Caucasian females with rheumatoid arthritis. Genet Epidemiol. 1998;15(2):123–34 [DOI] [PubMed] [Google Scholar]
- 27.Joshi R, Reveille JD, Brown MA, Weisman MH, Ward MM, Gensler LS et al. Is there a higher genetic load of susceptibility loci in familial ankylosing spondylitis? Arthritis Care Res (Hoboken) 2012. May;64(5):780–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Kawaguchi G, Kato N, Kashiwase K, Karaki S, Kohsaka T, Akaza et al. Structural analysis of HLA-B40 epitopes. Hum Immunol 1993. March;36(3):193–8 [DOI] [PubMed] [Google Scholar]
- 29.Espinoza LR, Vasey FB, Oh JH, Wilkinson R, Osterland CK. Association between HLA-BW38 and peripheral psoriatic arthritis. Arthritis Rheum 1978. January-February;21(1):72–5. [DOI] [PubMed] [Google Scholar]
- 30.Goyette P, Boucher G Mallon D, Ellinghaus E, Jostins L, Huang H, et al. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet. 2015. February;47(2):172–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP, et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology. 2000. February;118(2):274–8. [DOI] [PubMed] [Google Scholar]
- 32.El Mouraghi I, Ouarour A, Ghozlani I, Collantes E, Solana R, El Maghraoui A. Polymorphisms of HLA-A, -B, -Cw and DRB1 antigens in Moroccan patients with ankylosing spondylitis and a comparison of clinical features with frequencies of HLA-B*27. Tissue Antigens. 2015. February;85(2):108–16. [DOI] [PubMed] [Google Scholar]
- 33.Santos AM, Peña P, Avila M, Briceño I, Jaramillo C, Vargas-Alarcon G, et al. Association of human leukocyte A, B, and DR antigens in Colombian patients with diagnosis of spondyloarthritis. Clin Rheumatol. 2017. April;36(4):953–958 [DOI] [PubMed] [Google Scholar]
- 34.Londono J, Santos AM, Peña P, Calvo E, Espinosa LR, Reveille JD, et al. Analysis of HLA-B15 and HLA-B*27 in spondyloarthritis with peripheral and axial clinical patterns BMJ Open. 2015. November 11;5(11):e009092. doi: 10.1136/bmjopen-2015-009092. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Khan MA, Kushner I, Braun WE (1976) Letter: Low incidence of HLA-B*27 in American Blacks with spondyloarthropathies.Lancet 1976; 1 (7957):483. [DOI] [PubMed] [Google Scholar]
- 36.Robinson PC, Claushuis TA, Cortes A, Martin TM, Evans DM, Leo P, et al. Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis. Arthritis Rheumatol.2015. January;67(1):140–51 [DOI] [PMC free article] [PubMed] [Google Scholar]